Pulse Biosciences (PLSE) Corporate presentation summary

Mission and leadership

• Aims to design, produce, and commercialize nano-pulse technology to improve patient outcomes, focusing on high-quality, reliable products developed with rigorous standards.

• Leadership team includes experienced technologists, operators, and clinicians with backgrounds from major healthcare and medical device organizations.

Financial and strategic position

• Ended 2025 with $80.7 million in cash and no debt, but reported a $54.1 million cash burn for the year as investment in clinical opportunities increased.

• Q4 2025 revenue was $264,000, with a strategic focus on electrophysiology (EP) cardio ablation products following strong clinical outcomes.

• Approximately 75% insider ownership.

Technology and intellectual property

• Nanosecond Pulsed Field Ablation (nsPFA) offers a nonthermal, energy-efficient ablation mechanism for deeper, safer, and faster tissue ablation.

• Over 250 patents globally, covering the nPulse platform from generator to electrodes, with protection extending beyond 2040.